Table 1.
Pre-symptomatic individuals vs. controls | ||
Protein | p value | Up or downregulateda |
TNF | 1.94E−07 | ↑ |
PRR16 | 2.68E−07 | ↑ |
CSF2 | 2.05E−06 | ↑ |
CCDC85C | 2.91E−06 | ↑ |
CASP8 | 3.72E−06 | ↑ |
IL33† | 5.45E−06 | ↑ |
FAM81A | 5.77E−06 | ↑ |
SELE | 8.44E−06 | ↑ |
HTRA1 | 1.39E−05 | ↑ |
MMP10 | 2.16E−05 | ↑ |
Patients vs. controls | ||
Protein | p value | Up or downregulateda |
TNF | 5.52E−26 | ↑ |
PRR16 | 9.82E−26 | ↑ |
S100A12 | 1.06E−24 | ↑ |
CSF2 | 3.33E−24 | ↑ |
CASP8 | 2.35E−23 | ↑ |
FAM81A | 6.74E−22 | ↑ |
MMP10 | 1.56E−21 | ↑ |
HTRA1 | 2.05E−20 | ↑ |
SELE | 2.30E−20 | ↑ |
ORM1, ORM2† | 5.80E−20 | ↑ |
Pre-symptomatic individuals vs. patients | ||
Protein | p value | Up or downregulatedb |
KCNB2† | 2.92E−04 | ↓ |
S100A12 | 7.41E−04 | ↑ |
EPB41L5† | 1.97E−03 | ↑ |
COL6A1 | 2.55E−03 | ↓ |
ZNF618† | 3.82E−03 | ↑ |
S100A12 | 4.32E−03 | ↑ |
TGFB3† | 4.43E−03 | ↓ |
CCDC85C | 6.28E−03 | ↑ |
CSF2 | 6.73E−03 | ↑ |
DSC3† | 6.90E−03 | ↑ |
SLC11A1† | 8.33E−03 | ↑ |
†Protein included uniquely in one of three top ten protein lists. An expression change based comparison in apre-symptomatic individuals or RA patients vs. controls and bRA patients vs. pre-symptomatic individuals
CASP8 caspase 8; CCDC85C coiled-coil domain containing 85C; COL6A1 collagen type VI alpha 1 chain; CSF2 colony-stimulating factor 2; DSC3 desmocollin 3; EPB41L5 erythrocyte membrane protein band 4.1 like 5; FAM81A family with sequence similarity 81 member A; HTRA1 HtrA serine peptidase 1; IL33 interleukin 33; KCNB2 potassium voltage-gated channel subfamily B member 2; MMP10 matrix metallopeptidase 10; ORM1, ORM2 orosomucoid 1, orosomucoid 2; PRR16 proline rich 16; S100A12 S100 calcium-binding protein A12; SELE selectin E; SLC11A1 solute carrier family 11 member 1; TGFB3 transforming growth factor beta 3; TNF tumor necrosis factor; ZNF618 zinc finger protein 618